COVINGTON

Bay Area Life Sciences Symposium

THURSDAY, MARCH 13, 2025

Time Slot	Session	Description
9:00 a.m. – 9:30 a.m.	*Registration and Continental Breakfast*	
9:30 a.m. – 9:40 a.m.	*Opening Remarks* **Scott Cunningham**, Partner, Covington	
9:40 a.m. – 10:40 a.m.	**Plenary Session One:** *Life Sciences Dealmaking in 2025* ▪ **Ingrid Rechtin**, Moderator, Partner, Covington ▪ **John Kollins**, Chief Executive Officer and Corporate Director, Respira Therapeutics ▪ **Grace Han McMahon**, Associate Vice President and Head, Pacific BD&L, Merck ▪ **Andrew Shediac**, Healthcare Investment Banking Director, TD Cowen ▪ **Amy Toro**, Partner, Covington	This panel will cover learning from recent life sciences corporate transactions, including licensing, collaborations, financings, and M&A. Topics to be addressed will include deal structuring, notable therapeutic areas and modalities, recommendations for execution, and trends to watch in the coming year.
10:40 a.m. – 10:50 a.m.	*Morning Break*	
10:50 a.m. – 11:50 a.m.	**Plenary Session Two:** *So You've Got Yourself a Promising Candidate – Planning Ahead for Commercialization* ▪ **Alexa Hansen**, Moderator, Partner, Covington ▪ **Scott Cunningham**, Partner, Covington ▪ **Mark Kafka**, Vice President, Intellectual Property & Transactions, Denali ▪ **Philip LoScalzo**, Chief Compliance Officer, ImmunityBio, Inc.	Early stage clinical trials have gone well, and your promising drug candidate is moving into pivotal clinical testing. As you look forward to FDA approval, what are the things that you should be thinking about now to best position your company to go commercial? The panelists will explore regulatory, healthcare compliance, IP, business strategy, and other considerations to help you plan ahead for commercialization.
11:50 a.m. – 12:50 p.m.	*Buffet Lunch & Networking*	
12:50 p.m. – 1:10 p.m.	**CovTalk Session:** *FDA and LDTs: What Happens Now?* ▪ **Amy Leiser**, Special Counsel, Covington	For decades, FDA's approach to regulating diagnostics has been in flux, and another major shift in regulation could be coming. The fate of FDA's Final Rule on laboratory developed tests (LDTs) is in the hands of the courts and the new Administration, and Congress could revive

Time Slot	Session	Description
		legislative reform efforts. This CovTalk session will explore the status and future of FDA regulation of diagnostics and the implications for drug development and commercialization.
1:10 p.m. – 1:20 p.m.	*Afternoon Break*	
1:20 p.m. – 2:20 p.m.	**Plenary Session Three:** *As AI Collides with The Drug Life Cycle, What Changes and What Doesn't?* ▪ **Joe Franklin**, Moderator, Special Counsel, Covington ▪ **Lisa Taylor Ash**, Chief Operating Officer & General Counsel, Shape Therapeutics Inc. ▪ **Einar Stole**, Partner, Covington ▪ **Tammy Tompkins**, Chief Legal Officer, Insitro ▪ **Lindsey Tonsager**, Partner, Covington	The increasing adoption of AI in all aspects of the life sciences can make it difficult to separate signal from noise. The panelists will explore AI use cases throughout the biopharma life cycle – from drug discovery and clinical development to the post-market – and discuss implications for IP, regulatory requirements, commercial transactions, and more.
2:20 p.m. – 2:30 p.m.	*Closing Remarks* **Scott Cunningham**, Partner, Covington	
2:30 p.m. – 3:30 p.m.	*Afternoon Reception*	